Emergex Announces R&D Collaboration with DEKA Research & Development Corp.
Earlier this year, Emergex submitted a notification to the FDA regarding the transfer of ownership of Zosano Pharma™s Microneedle Array Patch (MAP) epidermal drug delivery system to Emergex itself...
ABINGDON, United Kingdom, Nov. 17, 2023 (GLOBE NEWSWIRE) -- Emergex Vaccines Holding Limited (˜Emergex™), a clinical-stage biotechnology company addressing major global infectious diseases through...
Emergex and VIC plan to collaborate to further develop and commercialise Emergex™s proprietary T cell-based vaccine candidates as designated in Saudi Arabia and the agreed Territory (including GCC...
First-in-human intradermal administration of CoronaTcP„¢ was generally well-tolerated Evidence for generation of virus-specific effector and memory CD8+ T cells Data reinforce findings from trial of...
PRESS RELEASE Emergex Generates Chikungunya Ligandome, a Milestone in the Development of its T cell Adaptive Vaccine Peptides specific to Chikungunya (CHIKV) virus expressed on surfaces of infected...
The unraveling of Zosano Pharma has led to a drug delivery deal. With the company filing for bankruptcy in the wake of its rejection by the FDA, Emergex Vaccines has stepped in to provide a new home for its intradermal drug delivery system.
Abingdon, Oxon, UK, 12 October 2022 – Emergex Vaccines Holding Limited (‘Emergex’, or the ‘Company’), a clinical stage biotechnology company addressing major global infectious diseases through the development of fully synthetic CD8+ T cell Adaptive Vaccines, announces that it has acquired the assets of Zosano Pharma Corporation (Fremont, CA).
Abingdon, Oxon, UK, 28 July 2022 – Emergex Vaccines Holding Limited (‘Emergex’, or the ‘Company’), a clinical stage biotechnology company addressing major global infectious diseases through the development of fully synthetic CD8+ T cell Adaptive Vaccines, announces the manufacture of its universal/pandemic influenza vaccine, ready for Phase I clinical trials.
PRESS RELEASE Emergex Vaccines signs Heads of Terms for a Collaboration with Molecular Biology Institute of Paraná (IBMP) in Brazil Abingdon, Oxon, UK, 1 July 2022 – Emergex Vaccines Holding Limited...